RUBICON · NSE
Rubicon Research Limited
₹1,718.7
-0.21% (-₹3.6)
Prev. close
₹1,722.3
Volume
2,41,875
Delivery %
65.8%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Rubicon Research with a target price of ₹2,100, about 20% upside, driven by 40% revenue growth, 53% EBITDA ri…” | Siddhartha KhemkaMotilal Oswal Financial Services Ltd. | Rubicon Research | PENDING | |
| “Recommends buying Rubicon Research in the short term, citing a strong breakout from its recent consolidation phase with …” | Riyank AroraMehta Equities | Rubicon Research | HIT | |
| “Motilal Oswal initiated coverage on Rubicon Research with a 'Buy' rating and a price target of ₹740, projecting a 22% up…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Rubicon Research | HIT |
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Motilal Oswal initiated coverage on Rubicon Research with a Buy rating, citing robust R&D capabilities and improving pro…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Rubicon Research Ltd | — |
Fundamentals
About Rubicon Research Limited
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies. The company was incorporated in 1999 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Parag Suganchand Sancheti
Headquarters
Mumbai
Employees
1,290
Website
rubicon.co.inExchange
View on NSE ↗Key stats
Market cap
₹28,856.78 Cr
P/E ratio (TTM)
100.4
Dividend yield
0.09%
EPS (TTM)
₹17.36
Beta (1Y · daily vs NIFTY 50)
0.41
Shares float
5.53 Cr
EPS · quarter ended Jun 2026
₹5.08
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY25 | FY26 |
|---|---|---|
| ₹1,267.10 Cr | ₹1,753.96 Cr | |
EBITDA | ₹265.79 Cr | ₹407.96 Cr |
| — | ₹246.74 Cr | |
Diluted EPS | — | ₹15.31 |
Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, Net income, Pretax income, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Net income for Mar 2026 could not be checked against the company's own annual report: this page shows ₹246.74 Cr while the annual report gives ₹188.17 Cr (23.7% apart).
EBITDA for Mar 2026 could not be checked against the company's own annual report: this page shows ₹407.96 Cr while the annual report gives ₹321.49 Cr (21.2% apart).
09 · Balance Sheet
Annual
| Line item | FY25 | FY26 |
|---|---|---|
| ₹1,451.43 Cr | ₹2,326.71 Cr | |
| ₹417.61 Cr | ₹311.01 Cr | |
Stockholders' equity | ₹540.98 Cr | ₹1,288.82 Cr |
Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY25 | FY26 |
|---|---|---|
| — | ₹205.05 Cr | |
Investing cash flow | — | ₹-409.72 Cr |
| — | ₹283.07 Cr | |
Capital expenditure | — | ₹-229.17 Cr |
End cash position | — | ₹185.65 Cr |
Operating cash flow, Depreciation & amortization, Investing cash flow, Financing cash flow, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Oct 25–Dec 25(2Q) | Mar 26 | Jun 26 |
|---|---|---|---|
| Promoter | 59.99% | 59.86% | 59.76% |
| Public | 40.01% | 40.14% | 40.24% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Rubicon Research Limited | ₹28,274.08 Cr | ₹1,716.8 | 98.4 | 21.94 | 19.1% | 0.24 | +36.6% | +163.1% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
4 indices